Relationship Between Oxytocin Level, Trust, & Attachment in Individuals

Status Not yet recruiting

Clinical Trial Summary

We aim to assess the baseline oxytocin levels in individuals with borderline personality disorder and correlate those levels with social behavior, and compare the results with controls. Primary Hypothesis (H1): There is a significant difference in trust-related behavior as measured by oxytocin (OXT) levels between borderline personality disorder (BPD) patients and healthy controls. Secondary Hypotheses: H2: The trust-related behavior in BPD patients is significantly influenced by their level of emotional sensitivity. Specifically, higher emotional sensitivity in BPD patients is associated with lower trust-related behavior and vice-versa. H3: There is a significant correlation between trust-related behavior and childhood trauma in BPD patients. BPD patients with higher levels of reported childhood trauma will exhibit lower trust-related behavior compared to those with lower levels of trauma. H4: Trust-related behavior in BPD patients varies depending on their attachment styles. Specifically, BPD patients with insecure attachment styles will exhibit lower trust-related behavior compared to those with secure attachment styles. H5: There is a significant correlation between trust-related behavior and BPD severity. Patients with more severe BPD symptoms will exhibit lower trust-related behavior compared to those with less severe symptoms. H6: The levels of OXT in BPD patients will significantly correlate with their reported levels of emotional sensitivity, childhood trauma, attachment styles, and BPD severity. These hypotheses aim to address the complexities surrounding the modulation of trust-related behavior by oxytocin in BPD patients, taking into account various factors like emotional sensitivity, childhood adversity, attachment styles, and BPD severity. By testing these hypotheses, the study aims to provide a comprehensive understanding of the interplay between these factors in influencing trust-related behavior in BPD patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06045650
Study type	Observational
Source	State University of New York - Upstate Medical University
Contact
Status	Not yet recruiting
Phase
Start date	June 1, 2024
Completion date	September 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04856449` - DBT Skills Plus EMDR for BPD and Trauma	N/A
Active, not recruiting	`NCT04587518` - Five Factor Model Treatment for Borderline Personality Disorder	N/A
Recruiting	`NCT05651295` - A Precision Medicine Approach to Target Engagement for Emotion Regulation	N/A
Completed	`NCT03677037` - The Short-Term MBT Project	Phase 3
Not yet recruiting	`NCT05989529` - Delving Into Borderline Personality Disorder Clinical Trial Experiences
Completed	`NCT02518906` - Evaluation of AIT Study	N/A
Completed	`NCT02068326` - MBT in Groups for Adolescents With BPD or Subthreshold BPD Versus TAU - the M-GAB Randomized Controlled Trial	N/A
Recruiting	`NCT04296604` - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations	N/A
Terminated	`NCT02149823` - Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations	Phase 1
Completed	`NCT02108990` - Acetaminophen and Social Processes	Phase 2
Completed	`NCT02988037` - Adapted Dialectical Behaviour Therapy for Adolescents With Deliberate Self-Harm: A Pre-post Observational Study	N/A
Not yet recruiting	`NCT01683136` - Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality Disorder	N/A
Completed	`NCT01635556` - Evaluation of a Modified Dialectical Behavior Therapy Program	N/A
Completed	`NCT02397031` - Mindfulness and Interpersonal Effectiveness Skills in Borderline Personality Disorder	N/A
Terminated	`NCT01103180` - Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder	Phase 2
Terminated	`NCT01212588` - Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)	Phase 2
Terminated	`NCT00539188` - N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD	Phase 2
Recruiting	`NCT05398627` - Neurofeedback for Borderline Personality Disorder	N/A
Recruiting	`NCT03994510` - SHame prOpensity in bOrderline Personality Disorder	N/A
Recruiting	`NCT06005129` - Personality Change Study for Borderline Personality Disorder	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Relationship Between Oxytocin Level, Trust, and Attachment in Individuals With Borderline Personality Disorder

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms